[
    [
        {
            "time": "2019-04-17",
            "original_text": "华北制药：业绩增七成水分大 研发投入资本化率高",
            "features": {
                "keywords": [
                    "华北制药",
                    "业绩增长",
                    "研发投入",
                    "资本化率"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "华北制药：业绩增七成水分大 研发投入资本化率高",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-04-17",
            "original_text": "恒瑞医药一季度营收增长29% 净利11.93亿元 董事长孙飘扬未持股",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "营收增长",
                    "净利润",
                    "董事长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药一季度营收增长29% 净利11.93亿元 董事长孙飘扬未持股",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-04-17",
            "original_text": "医疗保健：抓住增速快和发展趋势中的医药子行业 荐8股",
            "features": {
                "keywords": [
                    "医疗保健",
                    "医药子行业",
                    "推荐股票"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医疗保健：抓住增速快和发展趋势中的医药子行业 荐8股",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-04-17",
            "original_text": "应收账款及票据激增六成四 博瑞医药拟冲科创板 对手多为上市公司",
            "features": {
                "keywords": [
                    "博瑞医药",
                    "应收账款",
                    "科创板",
                    "竞争对手"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "应收账款及票据激增六成四 博瑞医药拟冲科创板 对手多为上市公司",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-04-17",
            "original_text": "【天风医药】通化东宝：2018年预计将业绩低点，2019年有望恢复快速增长",
            "features": {
                "keywords": [
                    "通化东宝",
                    "业绩低点",
                    "恢复增长"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【天风医药】通化东宝：2018年预计将业绩低点，2019年有望恢复快速增长",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-04-17",
            "original_text": "【天风医药】行业事件点评：《推进养老服务发展的意见》出台，行业逐步规范并迎来新的发展机遇",
            "features": {
                "keywords": [
                    "养老服务",
                    "政策出台",
                    "行业发展"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "养老"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【天风医药】行业事件点评：《推进养老服务发展的意见》出台，行业逐步规范并迎来新的发展机遇",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 10,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-04-17",
            "original_text": "券商看好医药板块 多只医药指数估值仍待修复",
            "features": {
                "keywords": [
                    "券商",
                    "医药板块",
                    "估值修复"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "券商看好医药板块 多只医药指数估值仍待修复",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-04-17",
            "original_text": "【天风医药】恒瑞医药：一季报业绩稳定较快增长，潜在重磅产品不断取得研发新进展",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "一季报",
                    "业绩增长",
                    "研发进展"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【天风医药】恒瑞医药：一季报业绩稳定较快增长，潜在重磅产品不断取得研发新进展",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-04-17",
            "original_text": "【恒瑞医药】19Q1点评：业绩稳健增长，创新龙头步入收获时代",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "业绩增长",
                    "创新龙头"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【恒瑞医药】19Q1点评：业绩稳健增长，创新龙头步入收获时代",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-04-17",
            "original_text": "大参考：部分维生素企业停限产 涨价预期逐步发酵",
            "features": {
                "keywords": [
                    "维生素",
                    "停限产",
                    "涨价预期"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "大参考：部分维生素企业停限产 涨价预期逐步发酵",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]